Skip to content

Enter search text

Search scope

All the UW Current site

Helpful Links

Home
About
About
TLC-ART Pipeline
TLC-ART’s DcNP Platform
TLC-ART Concepts
News
People
Publications
Contact

University of Washington University of Washington

Students
Parents
Faculty & Staff
Alumni

Home
About
News
People
Publications
Contact

TLC-ART Program
News
CROI

CROI

TLC-ART PI’s Drs. Collier and Ho discussed innovation in first-in-human study at the 2018 Conference on Retroviruses & Opportunistic Infections (CROI).

Post navigation

Previous article

Dr. Jane Simone

Global WACh, Children and Women

News

LEAP and CROI in Denver
Dr. Ho and his team attended and contributed to the LEAP workshop and CROI in Denver, highlighting their development in Drug-combination nanoparticle technology. This innovative technology simplifies and scales up the formulation of multiple antiretrovirals into a single injectable for long-acting HIV therpay. During LEAP, Rodney updated attendees on the …Read »
2024 Conferences
Happy 2024! This year you can find us at CROI in Denver with Prof Rodney Ho presenting TLC-ART progress on LEAP Workshop and Dr Perazzolo presenting a poster on PBPK-driven dosing in pediatrics of LA-injectables. In July 2024, Prof Ho and Dr Perazzolo will attend the 25th International AIDS Conference …Read »
TLC-ART featured on POZ.com
Prof. Ho’s Laboratory is featured on POZ.com, an influential print and online brand for people living with and affected by HIV/AIDS. Highlighting pivotal developments in HIV treatment from 2023, the article echoes the findings of Perazzolo and colleagues at University of Washington TLC-ART program led by Prfo Ho. Their research …Read »
HIV first-line TLD as one injectable lasting 1 month may be possible
TLC-ART can transform first-line 3 drugs TLD (tenofovir/lamivudine/tenofovir) as one long-acting injectable lasting 1 month in nonhuman primates In a significant pharmaceutical breakthrough, researchers at our laboratory have successfully developed an innovative long-acting injectable version of the antiretroviral drug combination known as TLD, comprising tenofovir, lamivudine, and dolutegravir. This formulation, …Read »
Prof Rodney Ho presented at IAS 2023 in Brisbane
Sept 12, 2023 Prof Ho presented TLC-ART work at IAS in Brisbane last July. TLC-ART has proposed the transformation of the short-acting HIV treatment, TLD (Tenofovir, Lamivudine, Dolutegravir), into a long-acting, single-injection formula that is stable in vivo and in nonhuman primates. This new formulation addresses “pill fatigue” and offers …Read »
New study in JIAS highlights U.S. patient preferences for long-acting HIV treatment
The study explores preferences for long-acting antiretroviral therapy (LA-ART) regimens among people with HIV (PWH) in the United States.Read »

University of Washington

Connect with us:

Facebook
Twitter
Instagram
YouTube
LinkedIn
Pinterest

Accessibility
Contact Us
Jobs
Campus Safety
My UW
Rules Docket
Privacy
Terms
Newsletter

© 2024 University of Washington | Seattle, WA